ArticleJournal of human hypertension2026
Potential under-recognition of primary aldosteronism in young adults with hypertension.
Article in Journal of human hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aldosterone-to-renin ratio (ARR) is the primary screening test for primary aldosteronism (PA), but it is strongly influenced by renin activity, which varies with age. Fixed ARR thresholds may therefore under-recognize PA in younger adults. We retrospectively analyzed 14,750 hypertensive patients who underwent saline infusion testing for suspected PA. An ARR of 20 was consistently used as the local reference threshold, but confirmatory testing could proceed despite ARR < 20 when clinical suspicion was high. Baseline plasma renin activity (PRA), aldosterone concentration (ALD), and ARR were measured before saline infusion. Of 13,428 patients with calculable ARR, 8703 (64.8%) underwent saline infusion testing despite ARR < 20, and 1578 had confirmed PA. Among 3966 confirmed PA patients with classifiable age-ARR data, ARR < 20 occurred in 57.5, 50.6, 35.4, and 33.2% of patients aged <35, 35-44, 45-54, and ≥55 years, respectively. Increasing age remained associated with lower odds of ARR < 20 after adjustment for sex, body mass index, blood pressure, potassium, creatinine, and a documented adrenal nodule (adjusted OR per year, 0.975; 95% CI, 0.967-0.984). The gradient persisted after restricting analyses to patients without a documented adrenal nodule, with potassium ≥3.5 mmol/L and eGFR ≥60 mL/min/1.73 m². Younger adults with confirmed PA frequently had baseline ARR values below 20, largely with relatively preserved PRA. Although residual referral bias cannot be excluded, these findings support cautious, age-informed interpretation of ALD, PRA, and ARR.
Identifiers
42864372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.